DDInter704 DDInter669
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ertugliflozin
Everolimus {u} (Compound) upregulates {v} (Gene) TIPARP
TIPARP {u} (Gene) is upregulated by {v} (Compound) Amcinonide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ertugliflozin
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somapacitan
Somapacitan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ertugliflozin
Everolimus {u} (Compound) upregulates {v} (Gene) TIPARP
TIPARP {u} (Gene) is upregulated by {v} (Compound) Betamethasone
Betamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ertugliflozin
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ertugliflozin
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Betamethasone
Betamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ertugliflozin
Everolimus {u} (Compound) downregulates {v} (Gene) JADE2
JADE2 {u} (Gene) is upregulated by {v} (Compound) Amcinonide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ertugliflozin
Everolimus {u} (Compound) downregulates {v} (Gene) JADE2
JADE2 {u} (Gene) is upregulated by {v} (Compound) Betamethasone
Betamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ertugliflozin
Everolimus {u} (Compound) upregulates {v} (Gene) RGS2
RGS2 {u} (Gene) is downregulated by {v} (Compound) Liotrix
Liotrix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ertugliflozin
Everolimus {u} (Compound) downregulates {v} (Gene) HAT1
HAT1 {u} (Gene) is downregulated by {v} (Compound) Amcinonide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ertugliflozin
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Everolimus (Compound) upregulates TIPARP (Gene) and TIPARP (Gene) is upregulated by Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Ertugliflozin
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan and Somapacitan may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Everolimus (Compound) upregulates TIPARP (Gene) and TIPARP (Gene) is upregulated by Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Everolimus (Compound) downregulates JADE2 (Gene) and JADE2 (Gene) is upregulated by Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Ertugliflozin
Everolimus (Compound) downregulates JADE2 (Gene) and JADE2 (Gene) is upregulated by Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Everolimus (Compound) upregulates RGS2 (Gene) and RGS2 (Gene) is downregulated by Liotrix (Compound) and Liotrix may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Everolimus (Compound) downregulates HAT1 (Gene) and HAT1 (Gene) is downregulated by Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Ertugliflozin